A study to assess the efficacy, safety, pharmacokinetics and related genetic polymorphisms of sunitinib

A study to assess the efficacy, safety, pharmacokinetics and related genetic polymorphisms of sunitinib - PK analysis of anticancer agent for renal cancer

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000015553

Enrollment

Registered

2014-10-28

Start date

2014-10-28

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

renal cell carcinoma

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Patients with renal cell carcinoma 2. Patients taking sunitinib 3. Signed informed consent prior to blood sampling for this study.

Exclusion criteria

Exclusion criteria: No exclusion criteria

Design outcomes

Primary

Measure	Time frame
To assess PK/PD based on plasma concentration of sunitinib, as well as efficacy and safety.	—

Secondary

Measure	Time frame
To explore genetic polymorphisms relating to pharmacokinetics, efficacy, and safety of sunitinib.	—

Countries

Japan

Contacts

Public ContactYuta Ohno

Gifu University Hospital Department of Pharmacy

ohnoyuta@gifu-u.ac.jp058-230-6000(6986)

Outcome results